Comparison of Clinicopathologic Characteristics of Urothelial Carcinoma Between Patients After Renal Transplantation and on Dialysis

Background Urothelial carcinoma (UC) is a common complication after renal replacement therapy (RRT) among Chinese end-stage renal disease (ESRD) patients. It is unclear whether there are any differences in the clinicopathologic characteristics of UC between renal transplantation (RT) and dialysis patients; such differences could impact RRT modality selection. Methods We retrospectively reviewed clinicopathologic data for 27 RT patients and 40 dialysis patients who were diagnosed with UC in our center to explore differences in the clinicopathologic characteristics of UC and prognoses between the two groups. Results The median follow-up period was 92 months (2–137) for the RT group and 71 months (18–155) for the dialysis group. The demographic and baseline data showed no significant differences between the two groups. Upper urinary tract UC (UUC) occurred more frequently in the RT group (22 UUCs in 39 UCs), whereas bladder UC (BUC) predominated in the dialysis group (33 BUCs in 49 UCs) (P=0.025). The pathologic grading in the RT group was significantly higher than that in the dialysis group (P=0.046 for WHO1973 grading, P=0.026 for WHO2004 grading), whereas the difference in tumor stage was not significant (P=0.089). The RT group manifested a higher recurrence rate than the dialysis group (P=0.024). However, the overall and cancer-specific survival rates between the two groups were not significantly different (P=0.239 and P=0.818, respectively). Conclusion Certain traits of UC, including tumor site, pathologic grading, and recurrence-free survival, were notably different between RT and dialysis patients, but the overall and cancer-specific survival rates were similar.

[1]  A. Francés,et al.  Bladder transitional cell carcinoma and BK virus in a young kidney transplant recipient , 2013, Transplant infectious disease : an official journal of the Transplantation Society.

[2]  Pau-Chung Chen,et al.  Occupational exposure to herbs containing aristolochic acids increases the risk of urothelial carcinoma in Chinese herbalists. , 2013, The Journal of urology.

[3]  D. Rix,et al.  The management of transitional cell carcinoma (TCC) in a European regional renal transplant population , 2012, BJU international.

[4]  Y. Chiang,et al.  Urothelial cancer after renal transplantation: an update. , 2012, Transplantation proceedings.

[5]  T. Fang,et al.  Increased risk of cancer in chronic dialysis patients: a population-based cohort study in Taiwan. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[6]  K. Shu,et al.  Rictor-dependent AKT activation and inhibition of urothelial carcinoma by rapamycin. , 2012, Urologic oncology.

[7]  D. Toncheva,et al.  Urothelial carcinoma associated with Balkan endemic nephropathy. A worldwide disease. , 2011, Pathologie-biologie.

[8]  Y. Zhu,et al.  Association between urothelial carcinoma after renal transplantation and infection by human papillomavirus types 16 and 18. , 2011, Transplantation proceedings.

[9]  Pau-Chung Chen,et al.  Increased risks of upper tract urothelial carcinoma in male and female chinese herbalists. , 2011, Journal of the Formosan Medical Association = Taiwan yi zhi.

[10]  S. Melchior,et al.  Urological de novo malignancy after kidney transplantation: a case for the urologist. , 2011, The Journal of urology.

[11]  P. Chiang,et al.  Primary urothelial carcinoma of the upper urinary tract in dialysis patients with 5-year follow-up. , 2010, Japanese journal of clinical oncology.

[12]  A. Webster,et al.  The pattern of excess cancer in dialysis and transplantation. , 2009, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[13]  S. Chueh,et al.  Sirolimus does not absolutely abolish the occurrence/recurrence of urothelial carcinoma in renal transplant recipients. , 2008, Transplantation proceedings.

[14]  M. Fischereder Cancer in patients on dialysis and after renal transplantation. , 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[15]  Y. Hsueh,et al.  Arsenic exposure, urinary arsenic speciation, and the incidence of urothelial carcinoma: a twelve-year follow-up study , 2008, Cancer Causes & Control.

[16]  C. Decaestecker,et al.  Late onset of bladder urothelial carcinoma after kidney transplantation for end-stage aristolochic acid nephropathy: a case series with 15-year follow-up. , 2008, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[17]  J. Nortier,et al.  For patients taking herbal therapy--lessons from aristolochic acid nephropathy. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[18]  Y. Ko,et al.  Malignancies after renal transplantation in southern Taiwan: experience in one centre , 2007, BJU international.

[19]  J. D. van der Walt,et al.  Regression of post‐transplant Kaposi's sarcoma using sirolimus , 2006, International journal of clinical practice.

[20]  M. Sever,et al.  Health-related quality of life after kidney transplantation in comparison intermittent hemodialysis, peritoneal dialysis, and normal controls. , 2006, Transplantation proceedings.

[21]  Chi-hung Cheng,et al.  High cumulative incidence of urinary tract transitional cell carcinoma after kidney transplantation in Taiwan. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[22]  M. Meng,et al.  Treatment and outcome of invasive bladder cancer in patients after renal transplantation. , 2004, The Journal of urology.

[23]  R. Oberbauer,et al.  Health and Quality of Life Outcomes Health-related Quality of Life Outcomes after Kidney Transplantation , 2004 .

[24]  J. Nortier,et al.  Renal interstitial fibrosis and urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). , 2002, Toxicology.

[25]  Yen-Ta Chen,et al.  The outcome of post‐transplant transitional cell carcinoma in 10 renal transplant recipients , 2002, Clinical transplantation.

[26]  P. Vereerstraeten,et al.  Progression rate of Chinese herb nephropathy: impact of Aristolochia fangchi ingested dose. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[27]  D. Nicol,et al.  A comparison of the effects of dialysis and renal transplantation on the survival of older uremic patients. , 2000, Transplantation.

[28]  T. Tzai,et al.  Transitional Cell Carcinoma in Dialysis Patients , 2000, European Urology.

[29]  D. Nicol,et al.  Transitional cell carcinoma in renal transplant recipients: the influence of compound analgesics. , 1998, British journal of urology.

[30]  E. Will,et al.  Risk of neoplasia in renal transplant patients , 1995, The Lancet.

[31]  S. Chu,et al.  Urologic cancers in uremic patients. , 1995, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[32]  C. Chuang,et al.  Malignancy in renal transplant recipients. , 1992, Transplantation proceedings.

[33]  D. McCance,et al.  Development of bladder tumour containing HPV type 11 DNA after renal transplantation. , 1988, British journal of urology.

[34]  EINZ,et al.  UROTHELIAL CARCINOMA ASSOCIATED WITH THE USE OF A CHINESE HERB ( ARISTOLOCHIA FANGCHI ) , 2022 .